NASDAQ:BXRX Baudax Bio (BXRX) Stock Price, News & Analysis → A lot of people are making this costly mistake (From WealthPress) (Ad) Free BXRX Stock Alerts $0.02 +0.00 (+7.39%) (As of 02/29/2024) Add Compare Share Share Today's Range$0.02▼$0.0250-Day Range$0.02▼$0.0352-Week Range$0.01▼$3.47Volume310,800 shsAverage Volume281,029 shsMarket Capitalization$1.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Baudax Bio alerts: Email Address Ad Crypto 101 MediaAltcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!) About Baudax Bio Stock (NASDAQ:BXRX)Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.Read More BXRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BXRX Stock News HeadlinesOctober 18, 2023 | finance.yahoo.comBaudax Bio Announces Corporate UpdateOctober 2, 2023 | msn.comBaudax's (BXRX) Hemophilia A Drug Gets FDA's Orphan Drug TagMarch 29, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. September 28, 2023 | investorplace.comWhy Is Baudax Bio (BXRX) Stock Up 75% Today?September 28, 2023 | marketwatch.comBaudax Bio Shares Double After Orphan Drug Designation for TI-168September 28, 2023 | markets.businessinsider.comBaudax Bio: FDA Grants Orphan Drug Designation To TI-168 For Hemophilia A With InhibitorsSeptember 18, 2023 | finance.yahoo.comHere's Why Baudax Bio, Inc. (BXRX) Is a Great 'Buy the Bottom' Stock NowSeptember 7, 2023 | finance.yahoo.comBaudax Bio to Participate in the H.C. Wainwright Global Investment ConferenceMarch 29, 2024 | Crypto Swap Profits (Ad)Grab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.August 23, 2023 | finance.yahoo.comBaudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common StockAugust 17, 2023 | finance.yahoo.comBaudax Bio Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesAugust 16, 2023 | finance.yahoo.comBaudax Bio Reports Second Quarter 2023 Financial Results and Provides Business UpdateJune 30, 2023 | investorplace.comWhy Is Baudax Bio (BXRX) Stock Up 130% Today?June 8, 2023 | markets.businessinsider.comBaudax Bio (BXRX) Gets a Hold from Noble FinancialMay 22, 2023 | markets.businessinsider.comNoble Financial Sticks to Their Hold Rating for Baudax Bio (BXRX)May 15, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Cocrystal Pharma (COCP) and Baudax Bio (BXRX)May 12, 2023 | finanznachrichten.deBaudax Bio, Inc.: Baudax Bio Reports First Quarter Financial Results and Provides Business UpdateMay 12, 2023 | baystreet.caBaudax Improves on Q1 ResultsMay 12, 2023 | msn.comRecap: Baudax Bio Q1 EarningsMay 12, 2023 | finance.yahoo.comBaudax Bio Reports First Quarter Financial Results and Provides Business UpdateMay 3, 2023 | finance.yahoo.comBaudax Bio to Present at the Sidoti Virtual Investor ConferenceMay 1, 2023 | finance.yahoo.comBaudax Bio Announces Closing of $4 Million Public OfferingApril 27, 2023 | msn.comWhy NETGEAR Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionApril 27, 2023 | investorplace.comWhy Is Baudax Bio (BXRX) Stock Down 52% Today?April 27, 2023 | finance.yahoo.comBaudax Bio Announces Pricing of $4 Million Public OfferingApril 25, 2023 | msn.comBaudax Bio Soars after Positive Topline DataApril 25, 2023 | msn.comBaudax Bio's Nerve Blockade Aces Mid-Stage Study In Surgery PatientsSee More Headlines Receive BXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Baudax Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/16/2023Today3/29/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BXRX CUSIPN/A CIK1780097 Webwww.baudaxbio.com Phone484-395-2440Fax484-395-2471Employees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($9.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,790,000.00 Net MarginsN/A Pretax Margin-18,950.64% Return on EquityN/A Return on Assets-175.11% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.07 Sales & Book Value Annual Sales$1.27 million Price / Sales0.90 Cash FlowN/A Price / Cash FlowN/A Book Value($14.93) per share Price / Book0.00Miscellaneous Outstanding Shares52,460,000Free Float52,408,000Market Cap$1.14 million OptionableNot Optionable Beta1.57 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Geraldine A. Henwood Ph.D. (Age 72)President, CEO & Director Comp: $633.25kMike ChoiVice President of Financial Planning & AnalysisMs. Natalie McAndrew (Age 53)Consultant & Principle Accounting Officer Dr. Chan Kim Yong Ph.D. (Age 50)Chief Scientific Officer & Director Key CompetitorsTenax TherapeuticsNASDAQ:TENXComera Life SciencesNASDAQ:CMRACingulateNASDAQ:CINGBiodexa PharmaceuticalsNASDAQ:BDRXSciSparcNASDAQ:SPRCView All Competitors BXRX Stock Analysis - Frequently Asked Questions How have BXRX shares performed in 2024? Baudax Bio's stock was trading at $0.0220 at the beginning of the year. Since then, BXRX stock has decreased by 0.9% and is now trading at $0.0218. View the best growth stocks for 2024 here. When is Baudax Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our BXRX earnings forecast. How were Baudax Bio's earnings last quarter? Baudax Bio, Inc. (NASDAQ:BXRX) released its quarterly earnings data on Wednesday, August, 16th. The company reported ($1.49) earnings per share for the quarter, beating analysts' consensus estimates of ($2.04) by $0.55. When did Baudax Bio's stock split? Baudax Bio's stock reverse split on the morning of Wednesday, November 30th 2022. The 1-40 reverse split was announced on Wednesday, November 30th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Baudax Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Baudax Bio investors own include Sorrento Therapeutics (SRNE), Coty (COTY), NIO (NIO), VBI Vaccines (VBIV), ADMA Biologics (ADMA), Energy Transfer (ET), Remark (MARK), Designer Brands (DBI), Geron (GERN) and Matinas BioPharma (MTNB). Who are Baudax Bio's major shareholders? Baudax Bio's stock is owned by many different retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Arnold M Baskies, Geraldine Henwood, Richard S Casten and Winston J Churchill. View institutional ownership trends. How do I buy shares of Baudax Bio? Shares of BXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BXRX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Baudax Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.